Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 5/20 | 0.40 |
| ▸ | NOS1 | P29475 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340427 | 0.81 | CD274 (0.46) | LOXL2NOS3NOS1SLC6A4KCNH2 | |
| SCHEMBL13226822 | 0.80 | CYP2A6 (0.48) | KCNH2ADRA1DGRM5 | |
| Hydrochloric Acid SCHEMBL3338248 | 0.79 | KDM4E (0.46) | LOXL2NOS3NOS1SLC6A4KCNH2 | |
| SCHEMBL5959961 | 0.78 | ADRA1D (0.41) | KCNH2ADRA1DGRM5 | |
| SCHEMBL19442372 | 0.77 | LOXL2 (0.52) | LOXL2NOS3NOS1SLC6A4KCNH2 | |
| SCHEMBL19442430 | 0.77 | LOXL2 (0.52) | LOXL2NOS3NOS1 | |
| SCHEMBL4830164 | 0.77 | LOXL2 (0.52) | LOXL2NOS3NOS1GRM5 | |
| SCHEMBL18682238 | 0.77 | ADRA1D (0.39) | KCNH2ADRA1DGRM5 | |
| SCHEMBL25054279 | 0.76 | LOXL2 (0.48) | LOXL2ADRA1DGRM5 | |
| SCHEMBL2160824 | 0.76 | ADRA1D (0.43) | KCNH2ADRA1DGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442692-B2 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-28 | — | — | US | disclosed |
| WO-2006103342-A9 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2007-10-25 | — | — | WO | disclosed |
| EP-1707564-B1 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | disclosed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | LOXL2 3963/4885NOS3 845/4885NOS1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.